Obesity & Hunger Drug: New Insights
- A new treatment has been approved for Prader-Willi syndrome, a rare genetic disorder affecting up to 20,000 people in the U.S.
- Vykat XR, developed by Soleno, aims to address this core symptom.
- The annual cost of Vykat XR is approximately $466,200.Soleno anticipates broad coverage from both private and public insurers, resulting in minimal co-payments for patients.
The FDA has approved Vykat XR, a new drug offering hope for those suffering from Prader-Willi syndrome. This groundbreaking medication aims to control hyperphagia, the relentless, insatiable hunger that defines the condition. This news sparks interest as research into targeted therapies for rare genetic obesity, like this one, could provide new insights into general obesity treatments. Learn about the challenges of managing this disorder and explore how this new drug may drastically improve patient lives. News Directory 3 provides updates on the evolving landscape of obesity and hunger drugs.Discover what’s next in the fight against obesity.
New Drug Offers Hope for Prader-willi Syndrome
Updated June 18, 2025
A new treatment has been approved for Prader-Willi syndrome, a rare genetic disorder affecting up to 20,000 people in the U.S. The syndrome is characterized by an insatiable appetite known as hyperphagia. caregivers frequently enough resort to extreme measures such as locking food cabinets and securing garbage cans to manage the relentless hunger.
Vykat XR, developed by Soleno, aims to address this core symptom. While the drug may cause side effects like high blood sugar, increased hair growth, and fluid retention, many patients find the benefits outweigh the risks.
The annual cost of Vykat XR is approximately $466,200.Soleno anticipates broad coverage from both private and public insurers, resulting in minimal co-payments for patients. The company is providing the drug without charge to trial participants until more insurers offer reimbursement.
Following FDA approval, Soleno’s stock value increased by 40%, bringing the company’s valuation to nearly $4 billion as of early June.
Ali Foley Shenk, whose son Dean has Prader-Willi syndrome, recounted the challenges of managing his hunger. She recalled a time when Dean consumed an entire 20-ounce box of raisins after a cupboard was briefly left unlocked, leading to an emergency room visit.
“Its crazy,” said Foley Shenk, who lives in Richmond, Virginia. “All of a sudden, they flip.”
Jesse Richards, an internal medicine physician and the director of obesity medicine at the University of Oklahoma-Tulsa’s School of Community Medicine, believes that research into targeted therapies for rare genetic obesity, like Prader-Willi syndrome, can improve the understanding of brain pathways related to appetite.
“Understanding how more targeted therapies work in rare genetic obesity helps us better understand the brain pathways behind appetite,” said Richards.
What’s next
Acadia Pharmaceuticals and Aardvark Therapeutics are conducting Phase III clinical trials targeting different pathways of Prader-Willi syndrome. Simultaneously, numerous trials for general obesity are underway, despite uncertainties in U.S. medical research funding.